Revumenib Drives Durable CR/CRh Rates in KMT2A-rearranged and NMP1-mutant AML

Revumenib resulted in deep response rates, facilitating subsequent transplant in patients with KMT2A-rearranged or NMP1-mutant, relapsed/refractory acute myeloid leukemia.

Revumenib (SNDX-5613) resulted in deep response rates, facilitating subsequent transplant in patients with KMT2A-rearranged or NMP1-mutant, relapsed/refractory acute myeloid leukemia (AML), according to updated findings from the phase 1 portion of the AUGMENT-101 study (NCT04065399) presented at the 2022 ASH Annual Meeting.

The results indicated that 30% (n = 18) of evaluable patients (n = 60) achieved complete response (CR)/CR with partial hematologic recovery (CRh). The median duration of CR/CRh was 9.1 months (n = 18; 95% CI, 2.7-not reached) and 78% of patients achieved minimal residual disease (MRD) negativity.

“Revumenib resulted in durable responses in heavily pretreated patients with relapsed/refractory KMT2A- and NPM1-mutant disease, and demonstrated a clinically manageable safety profile,” the study authors wrote in the presentation.

Revumenib is a potent, selective menin-KMT2A interaction inhibitor that acts by competitively binding a groove within menin, disassembling abnormal transcription complexes in KMT2A-rearranged, NPM1-mutant, and other leukemia subtypes.

The study enrolled adult and pediatric patients with relapsed/refractory KMT2A-rearranged or NMP1-mutant AML.

Revumenib was given orally in 12-hour increments every 28 days, and accelerated titration into a rolling 6 design was used, wherein patients in arm A received 113 mg, 226 mg, 339 mg, and 276 mg of revumenib, and those in arm B received 113 mg, 226 mg, and 163 mg.

The primary objective was to define the safety, tolerability, and recommended phase 2 dose (RP2D) of the agent.

To qualify for the RP2D, no more than 1 of 6 evaluable patients could experience a dose-limiting toxicity (DLT); at least two-thirds of patients had to receive at least 80% of their dose in the first 2 treatment cycles; and the 24-hour area under the curve had to exceed 15,000 ng x hr/mL in at least two-thirds of patients.

The median pediatric (n = 8) and adult (n = 60) ages were 50.5 and 2.5 years, respectively. Most patients were female (n = 42; 62%) and had AML (n = 56; 82%). The median number of prior lines of therapy received was 4 (range, 1-12) and included stem cell transplant (n = 31; 46%) and venetoclax (Venclexta; n = 41; 60%).

Most patients had KMT2A rearrangements (n = 46; 68%), including translocations (9;11), (11;19), (4;11), (6;11), (11;17), and others. NPM1 mutations were present in 21% of patients (n = 14); co-occurring mutations were found in FLT3 (n = 14; 25%), RAS (n = 12; 29%), and TP53 (n = 4; 10%).

Most patients discontinued treatment (n = 66; 97%) because of progressive disease/lack of response (n = 39; 57%), transplant (n = 12; 18%), adverse effects (n = 7; 10%), consent withdrawal (n = 3; 4%), another reason (n = 3; 4%), or physician decision (n = 2; 3%).

Additional efficacy data demonstrated that 8% of patients (n = 5) achieved CR with incomplete platelet recovery (CRp) and 15% (n = 9) achieved a morphologic leukemia-free state (MLFS), for a best response rate of 53% (n = 32). When broken down by genetic alteration, the objective response rate (ORR) was 59% (n = 27) in the KMT2A-rearranged population and 36% (n = 5) in the NPM1-mutant population; the CR/CRh rates were 33% (n = 15) and 21% (n = 3), respectively.

A total of 48 patients were separately evaluated for efficacy in the RP2D cohorts. In this population, the best ORR was 52% (n = 25/48), with CR, CRh, CRp, and MLFS rates of 17% (n = 8), 10% (n = 5), 10% (n = 5), and 15% (n = 7), respectively. Seventy-seven percent of patients (n = 10/13) who achieved CR/CRh also achieved MRD negativity.

Investigators also demonstrated “downregulation of FLT3 transcription, inducing responses in patients with FLT3 co-mutations.”

The median time to CR/CRh was 1.9 months (range, 0.9-4.9).

The median overall survival was 7.0 months (95% CI, 4.3-11.6) in the KMT2A-rearranged and NPM1-mutant population (n = 60).

Ten patients in CR and 2 in CRp underwent hematopoietic stem cell transplant.

Regarding safety, which was evaluated in 68 patients, any-grade treatment-related adverse effects (TRAEs) included ECG QTc prolongation (53%), nausea (27%), vomiting (16%), differentiation syndrome (16%), diarrhea (10%), dysgeusia (7%), and decreased appetite (7%). Grade 3 or greater TRAEs included ECG QTc prolongation (13%), diarrhea (3%), anemia (3%), asthenia (2%), fatigue (2%), hypercalcemia (2%), hypokalemia (2%), neutropenia (2%), thrombocytopenia (2%), and tumor lysis syndrome (2%).

Asymptomatic, grade 3 QTc prolongation was the only DLT and treatment-emergent AE, occurring in 10% and 13% of patients treated at recommended phase 2 inclusive doses and all doses, respectively.

Differentiation syndrome occurred in 16% of patients, and all cases were grade 2 and responded to steroids with or without hydroxyurea.


Issa GC, Aldoss I, DiPersio JF, et al. The menin inhibitor revumenib (SNDX-5613) leads to durable responses in patients with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase 1 study. Blood. 2022;140(suppl 1):150-152. doi:10.1182/blood-2022-164849

Related Videos
Expert on AML
Expert on AML
Craig Sauter, MD
Experts on AML
Expert on AML
Experts on MDS
Expert on MDS
Expert on AML
Expert on AML
Experts on MDS
Related Content